Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 161 from CHF 159 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDGF:
- Medacta Group SA Reports Strong Growth in H1 2025
- Medacta Group SA Reports Robust H1 2025 Earnings
- Medacta Group SA Reports Strong H1 2025 Results with 19.8% Revenue Growth
- Medacta Group downgraded to Neutral from Buy at UBS
- Medacta Group price target raised to CHF 159 from CHF 146 at Morgan Stanley